Voxzogo Phase 3 Study Achieves Primary Endpoint with Significant Patient Improvements
BMRN is trading near its 52-week low of $49.259 (6.0% above the low).
Summary
BioMarin Pharmaceutical announced positive results from its Phase 3 study of Voxzogo, a treatment for hypochondroplasia, a genetic disorder causing dwarfism. The study met its primary endpoint, demonstrating statistically significant increases in annualized growth velocity and standing height among participants compared to placebo. This strong data significantly de-risks the drug's regulatory path and enhances its commercial potential. The company plans to submit a supplemental new drug application to the FDA in the third quarter, followed by submissions to European and other health authorities, which will be key catalysts to watch.
At the time of this announcement, BMRN was trading at $52.23 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $9.7B. The 52-week trading range was $49.26 to $66.28. This news item was assessed with positive market sentiment and an importance score of 8 out of 10. Source: Dow Jones Newswires.